Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PORT-3
i
Other names:
PORT-3, IMM65, invariant natural killer T-cells therapeutics, IMM60/NY-ESO-1 immunogenic peptides, PRECIOUS-01, iNKT therapeutics
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Portage
Drug class:
NY ESO 1 inhibitor
Related drugs:
‹
TAEST16001 (2)
BNT111 (1)
GSK3377794 (1)
TBI-1301 (1)
CMB305 (0)
GSK2241658A (0)
GSK3845097 (0)
GSK3901961 (0)
ID-LV305 (0)
IDC-G305 (0)
LYL132 (0)
LYL331 (0)
MultiTAA T cell therapy (0)
N201 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
PDC*lung (0)
TCRT-ESO-A2 (0)
VTP-600 (0)
CDX-1401 (0)
TAEST16001 (2)
BNT111 (1)
GSK3377794 (1)
TBI-1301 (1)
CMB305 (0)
GSK2241658A (0)
GSK3845097 (0)
GSK3901961 (0)
ID-LV305 (0)
IDC-G305 (0)
LYL132 (0)
LYL331 (0)
MultiTAA T cell therapy (0)
N201 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
PDC*lung (0)
TCRT-ESO-A2 (0)
VTP-600 (0)
CDX-1401 (0)
›
Associations
News
Trials
Filter by
Latest
7ms
PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
P1, N=15, Recruiting, Radboud University Medical Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
7 months ago
Trial completion date • Trial primary completion date • Immunomodulating
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
|
CD20 positive
|
PORT-3
over1year
PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
P1, N=15, Recruiting, Radboud University Medical Center | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
over 1 year ago
Trial completion date • Trial primary completion date • Immunomodulating
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
|
CD20 positive
|
PORT-3
2years
PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
P1, N=15, Recruiting, Radboud University Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
2 years ago
Trial completion date • Trial primary completion date • Immunomodulating
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
|
CD20 positive
|
PORT-3
almost4years
PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
P1, N=15, Recruiting, Radboud University
almost 4 years ago
Clinical • New P1 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
|
CD20 positive
|
PORT-3
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login